| Variables | Number of trials | (%) |
---|---|---|---|
Phase | II | 10 | (14) |
III | 57 | (80) | |
Unspecified | 4 | (6) | |
Type of Tumor | Breast | 13 | (18) |
Genitourinary | 10 | (14) | |
Gastrointestinal | 6 | (8) | |
Lung | 10 | (14) | |
Other solid tumors | 14 | (20) | |
Hematological | 12 | (17) | |
Any cancer | 6 | (8) | |
Publication | JCO | 52 | (73) |
NEJM | 17 | (24) | |
Lancet | 2 | (3) | |
Registry | Clinicaltrials.gov | 62 | (87) |
ISRCT | 5 | (7) | |
EudraCT | 2 | (3) | |
ANZCTR | 1 | (1) | |
NTR | 1 | (1) | |
Type of Intervention | Chemotherapy | 22 | (31) |
Targeted therapy | 26 | (37) | |
Chemotherapy and radiation | 6 | (8) | |
Surgery or radiation | 6 | (8) | |
Supportive care | 11 | (15) | |
Trial Initiation Period | 1994–2005 | 30 | (42) |
2006–2010 | 41 | (58) | |
Trial Result | Negative | 37 | (52) |
Positive | 34 | (48) | |
Funding Source | Non-pharma | 33 | (46) |
Pharma | 38 | (54) | |
Length of Trial | <  3 years | 30 | (42) |
≥  3 years | 41 | (58) | |
Protocols with endpoints | Primary endpoints | 71 | (100) |
Secondary endpoints | 71 | (100) | |
Exploratory endpoints | 28 | (39) |